Irish Veterinary R&D Pioneer TriviumVet Acquired by U.S. Group PBI-Gordon in Major International Milestone; Forms Strategic Alliance with Pegasus to Launch Innovative Veterinary Drug Portfolio
Waterford, Ireland – 6th May 2025— TriviumVet, the innovative Irish veterinary research and development company, has been acquired by U.S.-based PBI-Gordon Corporation, in a landmark deal that underscores Ireland’s growing reputation as a hub for world-class life sciences innovation.
As part of the acquisition, TriviumVet’s portfolio of new animal health therapeutics will now be commercialised in partnership with Pegasus Laboratories, a leading veterinary pharmaceutical company and part of the PBI-Gordon group of companies. TriviumVet will remain as an R&D center of excellence growing its team based in the sunny south east of Ireland. While the financial terms of the deal were not disclosed, it is understood to represent a substantial transaction within the veterinary life sciences sector.
Founded in Waterford by serial entrepreneur Louise Grubb, TriviumVet has rapidly emerged as a global leader in the development of treatments for chronic diseases in companion animals, particularly in cardiology, gastroenterology, pain management and renal disease. Grubb, who previously founded NutriScience and Q1 Scientific — both major success stories in the Irish biotech sector — has once again demonstrated the global impact of Irish innovation.
Joining her in TriviumVet’s journey was co-founder Tom Brennan, an experienced pharmaceutical executive and co-founder of EirGen Pharma, who brought a wealth of expertise in drug development and global pharmaceutical strategy. Together, Grubb and Brennan built a company that not only addressed critical unmet needs in veterinary medicine but also positioned Ireland at the forefront of veterinary scientific research.
TriviumVet have recently received FDA and EMA approvals for a variety of new animal drug therapies including for; feline hypertrophic cardiomyopathy (FDA), treatment of gastrointestinal disease (EMA) and neuropathic pain in dogs (FDA).With an agile team of research scientists, chemists, pharmacists and project managers TriviumVet have punched above their weigh in the international veterinary pharmaceutical industry and have achieved astounding success with multiple first in disease treatments for devastating diseases with no available treatments.
“This acquisition is a proud moment for the entire TriviumVet team and for Irish innovation,” said Louise Grubb, CEO of TriviumVet. “It validates our vision of building globally relevant veterinary therapeutics from Ireland, and we are excited to see our products reach veterinarians and pet owners worldwide through PBI-Gordon and Pegasus’s commercial strength.”
Steve Clifford, President and CEO of PBI-Gordon, commented: “TriviumVet’s pioneering R&D efforts and entrepreneurial spirit align perfectly with our mission to advance animal health. We are delighted to welcome the team to the PBI-Gordon family and look forward to bringing their novel therapies to market.”
The deal represents a significant win for Ireland’s growing life sciences sector, particularly in the southeast, with TriviumVet headquartered in the Waterford pharmaceutical hub. The company’s scientific and regulatory teams, based in Ireland, will now work closely with Pegasus to accelerate the launch of multiple innovative veterinary drugs over the coming years.
About TriviumVet
Founded in Waterford, TriviumVet specializes in developing first-in-class therapeutics for companion animals, addressing significant unmet needs in veterinary medicine with scientifically robust and commercially viable solutions.
About PBI-Gordon Corporation
Founded in 1947, PBI-Gordon is a 100% employee-owned company that delivers innovative solutions for the animal health, turf, and ornamental markets.
About Pegasus Laboratories
Pegasus Laboratories, Inc., a member of the PBI-Gordon group of companies, develops and manufactures high-quality veterinary pharmaceuticals for the U.S. and global markets.
Media Contact:
Sarah O’Connor
0868499601
See below for PBI Gordon's press release: